Meera Raghunathan

Regulatory calendar

Five FDA decisions to watch before the year ends

The next three months bring verdicts on a first-of-its-kind cancer immunotherapy, a twice-yearly cholesterol shot and a rare disease drug that has already been turned away once.

Oct. 5, 2026·FDA

Obesity drugs

Three takeaways from Europe's largest obesity research meeting

Muscle preservation, monthly dosing and what happens after patients stop treatment dominated four days of presentations in Vienna.

Oct. 1, 2026·Pharma

Health department opens funding program to speed early-stage trials

Officials say they will back proposals that compress the time between a first human dose and proof of concept, and are weighing changes to the traditional phased system.

Sept. 26, 2026·Clinical Trials

FDA begins review of Nordlicht's multiple sclerosis pill

It is the first time the agency has accepted an application for a drug of this type in both relapsing and progressive forms of the disease.

Sept. 23, 2026·FDA

Third round of Medicare price negotiations adds fifteen drugs, including the first physician-administered medicines

The list covers treatments that accounted for about $41 billion in spending last year. Negotiated prices take effect in 2028.

Sept. 16, 2026·Drug Pricing

Tracker/Patent cliff

Patents protect pharma profits. Track when the biggest ones expire.

Seven of the ten best-selling medicines in the world will lose U.S. exclusivity before 2031.

Updated Sept. 10, 2026·Pharma

Nine European drugmakers warn the region is losing ground on research

In a joint letter, the companies call for faster trial approvals and stronger intellectual property protection, and say investment is moving to the U.S. and China.

Sept. 8, 2026·Pharma